Company Overview: Baxter International Inc. is a medical device and pharmaceutical company incorporated in Delaware, headquartered in Deerfield, Illinois, classified in the surgical and medical instruments industry (SIC 3841), with fiscal year ending December 31, 2025 Financial Reporting Structure: The filing contains comprehensive financial statements, XBRL-formatted data, and detailed…

Our analysis rates this filing BEARISH. Baxter International faces a HIGH concern level (7.2/10) driven by multiple material risk factors converging during a critical transition period. The January 2025 Kidney Care divestiture is exceptionally recent, creating near-term execution risk while the…

Concern level: HIGH (7.2/10). Key factors: Two major divestitures (Bio Pharma Solutions Sept 2023, Kidney Care Jan 2025) create extended contingent liabilities and execution risk; Kidney Care divestiture occurred January 31, 2025 - very recent with full-year 2025 operational impact and transition service obligations extending into future periods; Sustained restructuring charges across three…

Notable risk changes: Kidney Care Business Divested January 31, 2025: Major business unit separation creates transition execution risk, ongoing service obligations, and indemnification contingencies. Company retains manufacturing supply and transition service agreement obligations extending into future periods.; Sustained Restructuring Activity: Restructuring charges recorded across all three years (2023-2025)…

The model predicts BAX will underperform the S&P 500 by about 0.0% over 30 days. This is model analysis for research, not investment advice.